(Q34318765)

1 August 2017

1 reference

title

Leishmaniasis: an update of current pharmacotherapy (English)

1 reference

1 August 2017

0 references

1

Shyam Sundar

1 reference

1 August 2017

Jaya Chakravarty

2

1 reference

PubMed ID

23256501

1 August 2017

language of work or name

English

0 references

publication date

21 December 2012

1 reference

Expert Opinion on Pharmacotherapy

1 August 2017

1 reference

1 August 2017

14

1 reference

1 August 2017

1

1 reference

1 August 2017

53-63

1 reference

Post-kala-azar dermal leishmaniasis.

1 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Leishmaniasis worldwide and global estimates of its incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Leishmania/HIV co-infections: epidemiology in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

The relationship between leishmaniasis and AIDS: the second 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Injectable paromomycin for Visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.755515

10.1517/14656566.2013.755515

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

23256501